April 16, 2018 / 1:33 PM / in 4 months

BRIEF-Bristol-Myers Squibb Says Cancer Drug Combo Reduces Death Risk By 42 Pct

April 16 (Reuters) - Bristol-Myers Squibb Co:

* OPDIVO PLUS LOW-DOSE YERVOY COMBINATION REDUCES THE RISK OF PROGRESSION OR DEATH BY 42% VERSUS CHEMOTHERAPY IN FIRST-LINE LUNG CANCER PATIENTS WITH HIGH TUMOR MUTATIONAL BURDEN (TMB)

* BRISTOL-MYERS SQUIBB - IN STUDY, YERVOY COMBINATION DEMONSTRATED SUPERIOR BENEFIT FOR CO-PRIMARY ENDPOINT OF PFS VERSUS CHEMOTHERAPY Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below